(-)-Epigallocatechin gallate

CHF 45.00
In stock
AG-CN2-0063-M02525 mgCHF 45.00
AG-CN2-0063-M100100 mgCHF 120.00
More Information
Product Details
Synonyms Epigallocatechin-3-gallate; EGCG; CCRIS 3729; Teavigo; NVP-XAA 723
Product Type Chemical
Formula C22H18O11
MW 458.4
Merck Index 14: 3526
CAS 989-51-5
RTECS KB5200000
Source/Host Chemicals Isolated from green tea.
Purity Chemicals ≥98% (HPLC)
Appearance Off-white to white powder.
Solubility Soluble in DMSO, ethanol, dimethylformamide and water.
Identity Determined by 1H-NMR and MS.
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Keep cool and dry.
Keep under inert gas.
Protect from light.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
After reconstitution, prepare aliquots and store at -20°C.
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Potent anticancer compound.
  • Anti-angiogenic. VEGF, VE-cadherin phosphorylation, matrix metalloproteinase and urokinase-plasminogen activator (uPA) inhibitor.
  • Anti-inflammatory. NF-κB inhibitor. Modulates chronic inflammatory diseases, such as type 2 diabetes, rheumatoid arthritis, inflammatory bowel disease.
  • COX-2 and inducible nitric oxide synthase (iNOS; NOS II) inhibitor.
  • Potent antioxidant. Protects cells from lipid peroxidation and DNA damage induced by reactive free radicals.
  • Regulates cancer cell growth, proliferation, transformation, survival, angiogenesis, apoptosis, invasion and metastasis.
  • Chemopreventive. Apoptosis inducer. Promotes cell cycle arrest.
  • Modulates signal transduction pathways including JAK/STAT, MAPK, PI3K/AKT, Wnt and Notch.
  • EGFR and HER-2 receptor signaling inhibitor.
  • MAPKs and activator protein-1 inhibitor.
  • Potent DYRK1A inhibitor (IC50=330nM).
  • mTOR suppressor.
  • IGF-I signaling inhibitor.
  • Proteasome inhibitor.
  • Telomerase and DNA methyltransferase inhibitor.
  • Selective and noncompetitive HAT inhibitor.  
  • Topoisomerase I and II inhibitor.
  • Hedgehog signaling (Hh) modulator. PTCH and Gli1 inhibitor.
  • Wnt signaling inhibitor.
  • Neuroprotective. Activates HO-1 by the ARE/Nrf2 pathway, protecting neurons against oxidative damage.
  • STAT-1 inhibitor.
  • Shows preventive cardiovascular and metabolic (obesity, insulin resistance, hypertension and hypercholesterolemia) effects.
  • Inhibits extracellular signal-related kinases (ERK), activates AMP-activated protein kinase (AMPK), modulates adipocyte marker proteins and down-regulates lipogenic enzymes as well as other potential targets.
  • Fatty acid synthase (FAS) inhibitor.
  • Autophagy stimulator.
Product References
  1. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation: Y.J. Surh, et al.; Mutat. Res. 480-481, 243 (2001) (Review)
  2. The specificities of protein kinase inhibitors : an update: J. Bain, et al.; Biochem. J. 371, 199 (2003)
  3. Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate: N. Khan, et al.; Cancer Res. 66, 2500 (2006) (Review)
  4. Inhibition of fatty acid synthase by polyphenols: W.X. Tian; Curr. Med. Chem. 13, 967 (2006) (Review)
  5. Green tea polyphenols as a natural tumour cell proteasome inhibitor: Q.P. Dou, et al.; Inflammopharmacology 16, 208 (2008) (Review)
  6. Chemoprevention with phytochemicals targeting inducible nitric oxide synthase: A. Murakami; Forum Nutr. 61, 193 (2009) (Review)
  7. Molecular basis for cancer chemoprevention by green tea polyphenol EGCG: H. Tachibana; Forum Nutr. 61, 156 (2009) (Review)
  8. Apoptosis by dietary agents for prevention and treatment of prostate cancer: N. Khan, et al.; Endocr. Relat. Cancer 17, R39 (2010) (Review)
  9. Targeting polyamines and biogenic amines by green tea epigallocatechin-3-gallate: E. Melgarejo, et al.; Amino Acids 38, 519 (2010) (Review)
  10. Green tea polyphenol epigallocatechin-3-gallate: inflammation and arthritis: R. Singh, et al.; Life Sci. 86, 907 (2010) (Review)
  11. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals: S.C. Gupta, et al.; Cancer Metastasis Rev. 29, 405 (2010) (Review)
  12. Updates of mTOR inhibitors: H. Zhou, et al.; Anticancer Agents Med. Chem. 10, 571 (2010) (Review)
  13. The role of nutraceuticals in the regulation of Wnt and Hedgehog signaling in cancer: F.H. Sarkar, et al.; Cancer Metastasis Rev. 29, 383 (2010) (Review)
  14. Use of STAT1 inhibitors in the treatment of brain I/R injury and neurodegenerative diseases: F.H. Ebner, et al.; Cent. Nerv. Syst. Agents Med. Chem. 11, 2 (2011) (Review)
  15. Weight control and prevention of metabolic syndrome by green tea: S. Sae-tan, et al.; Pharmacol. Res. 64, 146 (2011) (Review)
  16. Targeting cell signaling and apoptotic pathways by dietary agents: role in the prevention and treatment of cancer: M.K. Shanmugam, et al.; Nutr. Cancer 63, 161 (2011) (Review)
  17. Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds: Y. Li, et al.; J. Nutr. Biochem. 22, 799 (2011) (Review)
  18. Modulation of Nrf2/ARE pathway by food polyphenols: a nutritional neuroprotective strategy for cognitive and neurodegenerative disorders: G. Scapagnini, et al.; Mol. Neurobiol. 44, 192 (2011) (Review)
  19. Nutritional approaches to modulate oxidative stress in Alzheimer's disease: C.B. Pocernich, et al.; Curr. Alzheimer Res. 8, 452 (2011) (Review)
  20. Possible involvement of programmed cell death pathways in the neuroprotective action of polyphenols: S. Bastianetto, et al.; Curr. Alzheimer Res. 8, 445 (2011) (Review)
  21. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications: B.N. Singh, et al.; Biochem. Pharmacol. 82, 1807 (2011) (Review)
  22. Epigenetic diet: impact on the epigenome and cancer: T.M.  Hardy & T.O. Tollefsbol; Epigenomics 3, 503 (2011) (Review)
  23. Green tea EGCG, T cells, and T cell-mediated autoimmune diseases: D. Wu, et al.; Mol. Aspects Med 33, 107 (2012) (Review)
  24. Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans: R. De la Torre, et al.; Mol. Nutr. Food Res. 58, 278 (2014)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.